BMC infectious diseases · 2026
Association between changes in HBsAb levels and hepatic adverse events after HBsAg clearance in non-cirrhotic chronic hepatitis B patients.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Deng Wen, Chen Xiaoxue, Zhang Ziyu, Li Xinxin, Cao Weihua, Zhang Yaqin, Wang Shiyu, Yao Linmei, Wei Xin, Wang Shuojie, Gao Zixuan, Xie Yao, Li Minghui
Аннотация
OBJECTIVE: The relationship between changes in hepatitis B surface antibody (HBsAb) levels and hepatic adverse events after hepatitis B surface antigen (HBsAg) clearance remains unclear. This study aimed to investigate the correlation between HBsAb level changes and hepatic adverse events in non-cirrhotic patients following HBsAg clearance.
METHODS: We retrospectively analyzed patients with HBsAg seroclearance achieved via pegylated interferon-alpha (Peg-IFNα) therapy in the Department of Hepatology II at Beijing Ditan Hospital, Capital Medical University, from October 2008 to December 2023. Participants were stratified by baseline HBsAb levels into negative (< 10 mIU/mL), low (10-100 mIU/mL), medium (100-1000 mIU/mL), and high (≥ 1000 mIU/mL) groups. Based on HBsAb trends during follow-up, patients were categorized into declining, stable, and rising groups. The primary endpoint was the incidence of hepatic adverse events after HBsAg clearance.
RESULTS: A total of 390 patients were included, with a median age of 38 (32-44) years and a median follow-up of 53.50 (11.00-173.00) months. During follow-up, 4 cases of hepatic adverse events occurred, all in the declining group (4 cases, 3.05%), while none were observed in the stable or rising groups (P = 0.018). Changes in HBsAb levels were inversely correlated with the incidence of hepatic adverse events (rs = -0.125, P = 0.014).
CONCLUSION: Declining HBsAb levels after HBsAg clearance may be associated with an increased risk of hepatic adverse events.
CLINICAL TRIAL: This study was registered at ClinicalTrials.gov (ID: NCT04301908; registration date: 03/06/2020; https://register.
CLINICALTRIALS: gov/ ).
METHODS: We retrospectively analyzed patients with HBsAg seroclearance achieved via pegylated interferon-alpha (Peg-IFNα) therapy in the Department of Hepatology II at Beijing Ditan Hospital, Capital Medical University, from October 2008 to December 2023. Participants were stratified by baseline HBsAb levels into negative (< 10 mIU/mL), low (10-100 mIU/mL), medium (100-1000 mIU/mL), and high (≥ 1000 mIU/mL) groups. Based on HBsAb trends during follow-up, patients were categorized into declining, stable, and rising groups. The primary endpoint was the incidence of hepatic adverse events after HBsAg clearance.
RESULTS: A total of 390 patients were included, with a median age of 38 (32-44) years and a median follow-up of 53.50 (11.00-173.00) months. During follow-up, 4 cases of hepatic adverse events occurred, all in the declining group (4 cases, 3.05%), while none were observed in the stable or rising groups (P = 0.018). Changes in HBsAb levels were inversely correlated with the incidence of hepatic adverse events (rs = -0.125, P = 0.014).
CONCLUSION: Declining HBsAb levels after HBsAg clearance may be associated with an increased risk of hepatic adverse events.
CLINICAL TRIAL: This study was registered at ClinicalTrials.gov (ID: NCT04301908; registration date: 03/06/2020; https://register.
CLINICALTRIALS: gov/ ).